HUMATE-P 2400 UNIT / 15 ML — DIN 02261235
VON WILLEBRAND FACTOR (HUMAN) : 2400 UNIT / 15 ML ANTIHEMOPHILIC FACTOR (HUMAN) : 1000 UNIT / 15 ML · CSL BEHRING CANADA INC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is HUMATE-P?
HUMATE-P 2400 UNIT / 15 ML contains VON WILLEBRAND FACTOR (HUMAN) : 2400 UNIT / 15 ML ANTIHEMOPHILIC FACTOR (HUMAN) : 1000 UNIT / 15 ML. It is listed in the Health Canada Drug Product Database under DIN 02261235, held by CSL BEHRING CANADA INC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 09-Oct-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HUMATE-P used for?
Treatment/prevention of bleeding in hemophilia A (adults); treatment of spontaneous/trauma bleeding in VWD; prevention of excessive bleeding during/after surgery in VWD (adults and pediatrics).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Von Willebrand Factor And Coag. Fact. Viii In Comb cost around the world?
Von Willebrand Factor And Coag. Fact. Viii In Comb is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Belgium publishes a public; Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Czechia | max producer price (ex-factory) | 4 | 9 | CZK███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
| Belgium | public | 4 | 4 | EUR███.██ |
| Luxembourg | reimbursement | 4 | 4 | EUR███.██ |
21 pack listings across 16 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Von Willebrand Factor And Coag. Fact. Viii In Comb pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Von Willebrand Factor And Coag. Fact. Viii In Comb in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Von Willebrand Factor And Coag. Fact. Viii In Comb, across 10 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| CSL BEHRING CANADA INC | 3 | 3 | HUMATE-P | Sourceable in Canada |
| OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H | 2 | 2 | WILATE | Sourceable in Canada |
| GRIFOLS BIOLOGICALS LLC | 5 | 0 | ALPHANATE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2400 UNIT / 15 ML |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Single-use vial with diluent (sterile water for injection) and Mix2Vial filter transfer device. Available in 250/600 IU, 500/1200 IU, and 1000/2400 IU formats. |
| Storage | Do not refrigerate after reconstitution. Administer within 3 hours after reconstitution. (Specific temperature range for dry vial not in snippet). |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Von Willebrand Factor And Coag. Fact. Viii In Comb |
|---|---|
| ATC code | B02BD06 |
| AHFS class | 52:04.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02261235 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2261235 |
| Brand name | HUMATE-P |
| Generic / active ingredient | VON WILLEBRAND FACTOR (HUMAN) : 2400 UNIT / 15 ML ANTIHEMOPHILIC FACTOR (HUMAN) : 1000 UNIT / 15 ML |
| Market authorization holder | CSL BEHRING CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | B02BD06 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B02BD |
| Current status | MARKETED |
| Status date | 09-Oct-2007 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Intravenous administration only. Hemophilia A: 15-50 IU FVIII/kg depending on severity. VWD: 40-80 IU VWF/kg every 8-12 hours. Surgery: Loading dose 50-60 IU VWF/kg. Max rate 4 mL/min.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Serious thromboembolic events in VWD patients; potential to contain infectious agents (plasma-derived). Risk of inhibitor formation and hypersensitivity.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| HUMATE-P | 600 UNIT / 5 ML | POWDER FOR SOLUTION | CSL BEHRING CANADA INC | MARKETED | 02261219 |
| HUMATE-P | 1200 UNIT / 10 ML | POWDER FOR SOLUTION | CSL BEHRING CANADA INC | MARKETED | 02261227 |
| WILATE | 500 UNIT / 5 ML | POWDER FOR SOLUTION | OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H | MARKETED | 02286750 |
| WILATE | 1000 UNIT / 10 ML | POWDER FOR SOLUTION | OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H | MARKETED | 02286769 |
| ALPHANATE | 300 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | 02475561 |
| ALPHANATE | 500 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | 02475588 |
| ALPHANATE | 1200 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | 02475596 |
| ALPHANATE | 1500 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | 02475618 |
| ALPHANATE | 2000 UNIT | POWDER FOR SOLUTION | GRIFOLS BIOLOGICALS LLC | APPROVED | 02475626 |
2 · Same class — other molecules in ATC B02BD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Coagulation Factor Viii | ADVATE · ADYNOVATE · AFSTYLA · ALTUVIIIO · +34 more | 134 | 38 | Yes |
| Coagulation Factor Ix | ALPHANINE PWS INJ 1500UNIT/VIAL · ALPROLIX · BEBULIN VH 500UNIT/VIAL · BEBULIN VH INJ 1000UNIT/VIAL · +8 more | 33 | 16 | Yes |
| Von Willebrand Factor And Coag. Fact. Viii In Comb | ALPHANATE · HUMATE-P · WILATE | 10 | 5 | Yes |
| Coagulation Factor Ix, Ii, Vii And X In Comb | BERIPLEX P/N 1000 · BERIPLEX P/N 500 · OCTAPLEX | 4 | 4 | Yes |
| Coagulation Factor Viia | NIASTASE · NIASTASE RT | 11 | 3 | Yes |
| Factor Viii Inhibitor Bypassing Activity | FEIBA NF · FEIBA VH IMMUNO ANTI INHIBITOR | 5 | 2 | Yes |
| Coagulation Factor Xiii | CORIFACT 1250 · CORIFACT 250 | 2 | 2 | Yes |
| Thrombin | RECOTHROM · THROMBOGEN SPRAY KIT · VISTASEAL | 4 | 1 | Yes |
| Catridecacog | TRETTEN | 1 | 1 | Yes |
| Etranacogene Dezaparvovec | HEMGENIX | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B02B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B02BX | Avatrombopag · Concizumab · Eltrombopag · Emicizumab · Fostamatinib · +1 more | 23 | 15 |
| B02BC | Combinations · Epinephrine · Local Hemostatics · Thrombin | 23 | 6 |
| B02BA | Phytomenadione | 5 | 2 |
| B02BB | Fibrinogen, Human | 2 | 2 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADYNOVATE | ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED : 1000 UNIT | TAKEDA CANADA INC | MARKETED | 02498588 |
| ALPROLIX | RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN : 500 UNIT | SANOFI-AVENTIS CANADA INC | MARKETED | 02422913 |
| ALTUVIIIO | *ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, BDD), FC-VWF-XTEN FUSION PROTEIN : 4000 UNIT | SANOFI-AVENTIS CANADA INC | MARKETED | 02448157 |
| ELOCTATE | ANTIHEMOPHILIC FACTOR (RECOMBINANT BDD), FC FUSION PROTEIN : 500 UNIT | SANOFI-AVENTIS CANADA INC | MARKETED | 02430304 |
| ESPEROCT | ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, B-DOMAIN TRUNCATED), PEGYLATED : 2000 UNIT | NOVO NORDISK CANADA INC | MARKETED | 02490099 |
| JIVI | ANTIHEMOPHILIC FACTOR (RECOMBINANT, B-DOMAIN DELETED, PEGYLATED) : 1000 UNIT | BAYER INC | MARKETED | 02481774 |
| REBINYN | COAGULATION FACTOR IX (RECOMBINANT), PEGYLATED : 3000 UNIT | NOVO NORDISK CANADA INC | MARKETED | 02532964 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is HUMATE-P called?
The same molecule, Von Willebrand Factor And Coag. Fact. Viii In Comb, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| FANHDI | Latin | Czechia |
| HAEMATE P | Latin | Czechia |
| IMMUNATE STIM PLUS | Latin | Czechia |
| WILATE | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.